ArticleFrontiers in medicine2026
A descriptive multilevel analysis associating COVID-19 with polymyositis: from genetic markers and candidate mediators to clinical hematological profiles.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Observational studies suggest an association between Coronavirus Disease 2019 (COVID-19) and polymyositis (PM), but causal inference s limited by confounding. This study adopted a multilevel exploratory framework to investigate potential relationships. We used two-sample Mendelian randomization (MR) to assess the causal effect of severe COVID-19 on PM, multi-omic analyses to screen for potential mediators, and retrospectively compared hematological profiles between severe and non-sever COVID-19 cases. Design: A two-sample MR with mediation analysis and a single-center retrospective cohort analysis. Setting and participants: Genetic instruments for severe COVID-19 (exposure), PM (outcome) and candidate multi-omic mediators (91 inflammatory proteins, 4,907 circulating plasma proteins, 731 immune-cell traits, and 1,400 plasma metabolites) were obtained from genome-wide association studies (GWAS). The clinical study included 108 hospitalized patients with PCR-confirmed COVID-19, classified into severe and non-severe subgroups. Main outcomes: The main outcome in the MR analysis was the causal odds ratio (OR) of PM per genetically predicted increase in the risk of severe COVID-19. Secondary outcomes included the identification of mediating biomarkers and differences in hematological indices between severe and non-severe COVID-19 patients. Results: MR analysis suggested a potential causal effect of severe COVID-19 on PM (IVW OR = 1.65, 95% CI: 1.36-2.01, Conclusion: This multilevel exploratory study provides preliminary genetic evidence suggesting a potential association between severe COVID-19 and polymyositis, along with candidate molecular mediators. The clinical analysis revealed distinct hematological profiles in patients with severe COVID-19. These findings should be interpreted as preliminary clues rather than definitive mechanistic evidence. Future studies with independent validation cohorts, larger sample sizes, and longitudinal follow-up for incident myositis are needed to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.